Tuberculosis

Tuberculosis (TB) is a serious infectious disease primarily caused by the bacterium Mycobacterium tuberculosis. It predominantly affects the lungs (pulmonary TB), but can also affect other parts of the body (extrapulmonary TB) such as the lymph nodes, pleura, bones, joints, kidneys, and brain. TB is transmitted through airborne droplets when infected individuals cough, sneeze, or speak. While many infected individuals remain asymptomatic with latent TB infection, approximately 5-10% develop active TB disease, which can be fatal if left untreated. Global efforts are focused on diagnosis, treatment, and prevention to reduce its significant public health burden.

Tuberculosis is caused by infection with Mycobacterium tuberculosis complex, primarily M. tuberculosis. Transmission occurs via inhalation of airborne droplet nuclei containing the bacteria, expelled by individuals with active pulmonary TB. Factors influencing transmission include duration of exposure, proximity to the infected person, and the infectiousness of the source case. Lifestyle factors such as overcrowding and poor ventilation facilitate spread. There are no direct genetic factors determining susceptibility, but certain genetic polymorphisms may influence immune response.

Upon inhalation, M. tuberculosis bacilli reach the alveoli, where they are ingested by alveolar macrophages. If the macrophages fail to eliminate the bacteria, the bacilli multiply intracellularly. The host immune system mounts a cellular response, forming a granuloma – a localized collection of immune cells (macrophages, lymphocytes, epithelioid cells, giant cells) – to contain the infection. This containment leads to latent TB infection (LTBI). If the immune system is compromised, the granuloma can break down, allowing bacilli to multiply and disseminate, leading to active TB disease. This can involve caseous necrosis and cavitation in the lungs, facilitating airborne transmission. Dissemination can also lead to extrapulmonary TB.

Tuberculosis remains one of the leading causes of death from a single infectious agent globally. In 2022, the WHO estimated 10.6 million people fell ill with TB, and 1.3 million died. Incidence is highest in Southeast Asia, Africa, and the Western Pacific. Age distribution shows higher rates in young adults, but all age groups are susceptible. Men generally have higher incidence rates than women globally, but prevalence in women is significant, especially in reproductive ages. HIV co-infection is a major driver of the TB epidemic, particularly in sub-Saharan Africa. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges.

• HIV infection
• Immunosuppression (e.g., organ transplant recipients, TNF-alpha inhibitors, high-dose corticosteroids)
• Close contact with an active TB patient
• Malnutrition
• Diabetes mellitus
• Chronic kidney disease
• Silicosis
• Substance abuse (alcoholism, intravenous drug use)
• Smoking
• Overcrowding and poor living conditions
• Healthcare workers with occupational exposure

A. Early Symptoms

• Mild cough


• Low-grade fever


• Fatigue B. Common Symptoms


• Persistent cough (often productive, lasting >2-3 weeks)


• Fever


• Night sweats


• Unexplained weight loss


• Fatigue/Malaise


• Loss of appetite


• Chest pain (if pleura involved) C. Advanced Symptoms


• Hemoptysis (coughing up blood)


• Dyspnea (shortness of breath)


• Hoarseness (laryngeal TB)


• Swollen, painful lymph nodes (extrapulmonary TB)


• Back pain, paralysis (spinal TB)


• Headache, confusion (meningeal TB)


• Abdominal pain, diarrhea (gastrointestinal TB) D. Emergency Symptoms


• Massive hemoptysis


• Severe respiratory distress


• Altered mental status (suggesting meningeal TB)


• Sudden onset high fever with chills and severe prostration (miliary TB with septic shock)

• Vital signs: Low-grade fever, tachycardia.
• Inspection: Cachexia, pallor, visible lymphadenopathy (cervical, axillary, inguinal).
• Palpation: Tactile fremitus may be increased over consolidated areas; tenderness over affected bones/joints in extrapulmonary TB.
• Percussion: Dullness over areas of consolidation or pleural effusion.
• Auscultation: Crackles (rales), bronchial breath sounds, rhonchi over affected lung fields; diminished breath sounds with pleural effusion; egophony.

A. Clinical Assessment: Detailed history of symptoms, exposure, risk factors.
B. Laboratory Testing: Sputum smear microscopy, culture, NAAT, IGRA, TST.
C. Imaging Studies: Chest X-ray, CT scan.
D. Functional Tests: Not routinely diagnostic for active TB; pulmonary function tests may assess post-TB lung damage.
E. Biopsy Findings: Histopathological evidence of granulomas with caseous necrosis from affected tissue (lung, lymph node, pleura).
F. Genetic Testing: Nucleic Acid Amplification Tests (NAAT) for rapid detection and identification of M. tuberculosis and resistance to rifampicin. Genotypic resistance testing for other drugs.
G. Differential Diagnosis: Pneumonia, lung cancer, sarcoidosis, fungal infections, non-tuberculous mycobacterial infections.

Acid-Fast Bacilli (AFB) Smear Microscopy
Type: Sputum Test
Purpose: Rapidly detect acid-fast bacilli in respiratory samples.
Expected Findings: Presence of red-stained bacilli against a blue background.
Interpretation: Positive result suggests mycobacterial infection, likely TB; rapid indicator of infectiousness. Mycobacterial Culture (Solid and Liquid Media)
Type: Sputum Test / Tissue / Fluid Culture
Purpose: Definitive diagnosis of TB and drug susceptibility testing.
Expected Findings: Growth of M. tuberculosis colonies; positive growth control.
Interpretation: Gold standard for TB diagnosis; identifies specific species and allows for drug resistance profiling. Nucleic Acid Amplification Test (NAAT) e.g., Xpert MTB/RIF
Type: Sputum Test / Tissue / Fluid Test
Purpose: Rapid detection of *M. tuberculosis

• DNA and rifampicin resistance.

Chest X-ray (CXR)
Purpose: Initial imaging for suspected pulmonary TB.
Typical Findings: Cavitary lesions (upper lobes), infiltrates, hilar lymphadenopathy, pleural effusions, miliary patterns (disseminated TB).
Clinical Importance: Helps identify active pulmonary disease, monitor treatment response, and screen contacts. Computed Tomography (CT) Scan of Chest
Purpose: Further evaluate findings from CXR, detect subtle lesions, assess extent of disease, guide biopsies.
Typical Findings: Greater detail of cavities, consolidations, tree-in-bud opacities (bronchogenic spread), pleural thickening, lymphadenopathy, bone involvement (Pott's disease).
Clinical Importance: Provides more detailed anatomical information, crucial for complex cases, extrapulmonary TB, and surgical planning.

• Bacterial Pneumonia: Acute onset, typically lobar consolidation, rapid response to broad-spectrum antibiotics.
• Fungal Infections (e.g., Histoplasmosis, Coccidioidomycosis): Geographically specific, similar granulomatous lesions, specific fungal cultures/serology.
• Lung Cancer: Mass lesions, often in smokers, biopsy reveals malignancy.
• Non-tuberculous Mycobacterial (NTM) Disease: Clinically and radiologically similar, requires specific mycobacterial culture identification and susceptibility testing.
• Sarcoidosis: Non-caseating granulomas, hilar lymphadenopathy, often multisystemic, diagnosis by exclusion.
• Bronchiectasis: Chronic cough with purulent sputum, characteristic imaging findings.

• Pulmonary: Hemoptysis, pneumothorax, bronchiectasis, chronic destructive lung disease (post-TB fibrosis), aspergilloma formation in cavities.
• Pleural: Pleural effusion, empyema, constrictive pericarditis.
• Disseminated/Miliary TB: Widespread systemic disease, high mortality.
• Extrapulmonary: Spinal deformity and paralysis (Pott's disease), adrenal insufficiency (Addison's disease), renal failure, neurological deficits (tuberculous meningitis), infertility (genital TB).
• Treatment-related: Drug-induced hepatitis, peripheral neuropathy, optic neuritis, ototoxicity, nephrotoxicity.

A. Lifestyle Modifications: Nutritional support, rest, avoidance of smoking and alcohol.
B. Preventive Measures: BCG vaccination (for infants in endemic areas), Isoniazid Preventive Therapy (IPT) or other short-course regimens for LTBI.
C. Medical Treatment:
First-line anti-TB drugs (for drug-susceptible TB): Intensive Phase (2 months): Isoniazid (INH), Rifampicin (RIF), Pyrazinamide (PZA), Ethambutol (EMB).

• Continuation Phase (4-7 months): Isoniazid, Rifampicin.


• Mechanism: Bactericidal (INH, RIF, PZA) and bacteriostatic (EMB); target bacterial cell wall synthesis, RNA synthesis, and cell metabolism.


• Second-line anti-TB drugs (for drug-resistant TB): Fluoroquinolones (e.g., Moxifloxacin), injectables (e.g., Amikacin, Kanamycin), Bedaquiline, Pretomanid, Linezolid, Delamanid. Treatment regimens are highly individualized and extended (6-24 months) for MDR/XDR-TB.

With prompt and appropriate treatment, drug-susceptible TB has an excellent prognosis, with cure rates exceeding 90%. Delay in diagnosis or treatment significantly worsens outcomes. Drug-resistant TB (MDR/XDR-TB) carries a much poorer prognosis, with lower cure rates (MDR-TB ~60-70%, XDR-TB ~30-40%) and higher mortality, even with prolonged, complex regimens. Long-term outcomes for survivors may include chronic lung damage, bronchiectasis, and reduced lung function.

• Primary Prevention: BCG vaccination (for infants in high-burden settings), improving living conditions, infection control measures (ventilation, UV light) in healthcare settings.
• Secondary Prevention: Screening and treatment of latent TB infection (LTBI) in high-risk individuals, contact investigation, rapid diagnosis and prompt treatment of active TB to interrupt transmission.
• Screening: Targeted TST or IGRA for high-risk groups (contacts, immunocompromised).

The following homeopathic remedies have been historically indicated for symptoms associated with Tuberculosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Tuberculosis.